Rigel Pharmaceuticals Inc.

09/05/2024 | Press release | Distributed by Public on 09/05/2024 05:37

Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML